Nuevos fármacos antituberculosos / New antituberculous drug
Acta méd. peru
; 26(4): 247-250, oct.-dic. 2009.
Article
in Es
| LILACS, LIPECS
| ID: lil-565484
Responsible library:
PE1.1
RESUMEN
La tuberculosis es una enfermedad infectocontagiosa que en pleno siglo XXI continúa siendo un flagelo mundial y que amenza a la humanidad con nuevas formas emergentes de tuberculosis multidrogo resistente (MDR) y la extremadamente resistente a todos los medicamenteos conocidos, la tuberculosis XDR. En este contexto son pocos los nuevos mediamentos antituberculosos desarrollados por la industria farmaceútica, por lo que el esquema terapéutico contra esta antigua enfermedad no ha variado sustancialmente. Hoy todos los seres humanos estamos expuestos y en peligro de contagiarnos de tuberculosis y por ende tener que iniciar prolongados tratamientos o tal vez enfrentar la muerte por falta de acción efectiva de éstos contra el germen productor de la tuberculosis.
ABSTRACT
Tuberculosis (TB) is a communicable disease that is still a very important health problem in the 21st Century, and it is currently threatening mankind with the emergence of new multidrug resistant (MDR) and extremely resistant (XDR) strains of its causative agent, Mycobacterium tuberculosis. In this scenario, there are very few new antituberculous drugs developed by the pharmaceutical industry, so the therapeutic strategy for this old disease has not undergone substantial changes. Nowadays, every human being is at risk for exposure and for acquiring tuberculosis, so that people acquiring the disease may be exposed to a prolonged therapy schedule, or they may even face death because of lack of effectiveness of antituberculous drugs in MDR or XDR TB cases.
Key words
Full text:
1
Index:
LILACS
Main subject:
Tuberculosis
/
Tuberculosis, Multidrug-Resistant
/
Antitubercular Agents
Limits:
Humans
Language:
Es
Journal:
Acta méd. peru
Journal subject:
MEDICINA
Year:
2009
Type:
Article